The Aufzien Family Center for the Prevention and Treatment of Parkinson's Disease at Tel Aviv University, in collaboration with the Neurological Institute at the Tel Aviv Sourasky Medical Center, will deepen the understanding of and develop novel treatments for Parkinson's Disease.
- Expand the understanding of the molecular basis and biological mechanisms of PD
- Identify PD biomarkers
- Develop technologies and/or drug candidates for pre-clinical and clinical evaluation
- Promote a productive exchange of ideas among academia, hospitals, physicians, paramedical teams, HMO and industry
- Become a world-renowned hub of R&D in the field
The APPD Center will support a holistic process that encompasses the entire drug development cycle from basic research through commercialization. This includes garnering a deep understanding of the progression of the disease, as well as developing interventions.
The Center will:
- Support novel basic research projects
- Develop and validate biological markers in the lab and clinics at TAU and TAU-affiliated medical centers and HMO's
- Develop and test non-pharmacological interventional technologies for prevention and modulation of disease
- Test drug candidates for viability at TAU's state-of-the-art Blavatnik Center for Drug Discovery
Jump start clinical trials on successful drug candidates via TAU's SPARK Global Initiative for Translational Medicine
- Patent and license successful drugs through Ramot, TAU's commercialization company